{"id":562,"date":"2018-06-12T14:22:01","date_gmt":"2018-06-12T18:22:01","guid":{"rendered":"https:\/\/research.ncsu.edu\/win\/?p=562"},"modified":"2024-01-08T16:44:28","modified_gmt":"2024-01-08T21:44:28","slug":"will-durhams-emergo-therapeutics-be-fourth-big-startup-hit-for-moise-khayrallah","status":"publish","type":"post","link":"https:\/\/research.ncsu.edu\/win\/will-durhams-emergo-therapeutics-be-fourth-big-startup-hit-for-moise-khayrallah\/","title":{"rendered":"Will Durham\u2019s Emergo Therapeutics be fourth big startup hit for Moise Khayrallah?<\/a>"},"content":{"rendered":"\n\n\n\n

DURHAM \u2013<\/strong>\u00a0Moise Khayrallah, Ph.D., is a serial entrepreneur with a Midas touch. Three biopharmaceutical start-ups he co-founded in recent years were quickly sold to larger companies for more than $400 million after he and his teams built their value from scratch.<\/p>\n

His latest startup, Durham-based\u00a0Emergo Therapeutics<\/a>, could be on a similar path after raising $12 million in venture capital this spring, mostly from North Carolina investors.<\/p>\n

\u201cFor me, this is a huge shot in the arm, not just for us as a company but for the entrepreneurial community in our area,\u201d says Khayrallah, noting the state\u2019s modest venture capital resources relative to those of other leading bioscience regions such as Greater Boston and California\u2019s Bay Area.<\/p>\n

His advice to other bioscience entrepreneurs in North Carolina: \u201cLook, if you do this right, there is money to be had here, and you can raise substantial funds for your project if you know how to do it. Don\u2019t be shy. Don\u2019t be scared.\u201d<\/p>\n

The Series A investment in Emergo was led by Raleigh-based Rex Health Ventures, the venture capital arm of the UNC REX Healthcare hospital system.<\/p>\n

Other investors included the Venture Capital Multiplier Fund at Hatteras Venture Partners of Durham, the Wolfpack Investor Network and the Carolina Angel Network. The latter two groups are the angel investment networks of North Carolina State University and the University of North Carolina at Chapel Hill, respectively, and they \u201ccame in very big for us,\u201d Khayrallah says.<\/p>\n

Emergo is the first pharmaceutical company that either angel network has invested in, and their investments are their largest to date in any company, he notes.<\/p>\n

\u201cThis is why I\u2019m excited about this,\u201d he says. \u201cIf this small company with one project was able to raise $12 million, the bulk of it from here (in North Carolina), there is hope for the entrepreneurs out there.\u201d<\/p>\n

Khayrallah and Robin Hyde-DeRuyscher, Emergo\u2019s co-founder and chief scientific officer, positioned the company for the venture round with the help of a $75,000 Company Inception Loan in 2017 from the North Carolina Biotechnology Center.<\/p>\n

TARGETING FLU AND FLU-LIKE ILLNESSES<\/h3>\n

\u201cIn flu and other viruses that are similar to the flu, the virus itself does not cause the damage,\u201d Khayrallah says. \u201cThe virus is very innocuous.\u201d<\/p>\n

Rather, he says, an over-response to the virus by the body\u2019s innate immune system is responsible for flu symptoms such as fever, chills, fatigue, sore throat and aches.<\/p>\n

\u201cWhen the immune system gears up like that, it really wreaks havoc on the body,\u201d he says.<\/p>\n

Some of the immune response comes from a type of white blood cell called mast cells that release a flood of powerful chemical mediators including histamine, heparin, cytokines, leukotrienes, proteases and granulocyte macrophage colony-stimulating factor.<\/p>\n

\u201cOur drug helps modulate these mast cells\u2019 chemical signaling,\u201d he says. \u201cThe idea is to help tone down the immune system in certain conditions when the immune system gets geared up in an inappropriate fashion.\u201d<\/p>\n

Norketotifen is a metabolite, or byproduct, of ketotifen, an antihistamine that stabilizes mast cells and has been used to treat asthma, allergies and conjunctivitis for four decades under various brand names including Zaditor and Alaway.<\/p>\n

\u201cWe tend to gravitate toward molecules that are very well known,\u201d Khayrallah says. \u201cHow do we tweak them, how do we modify them to where we can benefit more from them while capitalizing on what we already know? This is the core expertise that we\u2019ve developed over the years, my team and I.\u201d<\/p>\n

By reining in the body\u2019s immune response to flu and flu-like illnesses, norketotifen may help spare patients the miserable symptoms and complications that can lead to hospitalization and even death.<\/p>\n

\u201cWe are starting with the flu even though we know there is a slew of other potential diseases or illnesses that we can tackle,\u201d Khayrallah says.<\/p>\n

CLINICAL TRIALS ON HORIZON<\/h3>\n

Next steps in the development of norketotifen will be toxicology studies, manufacturing preparation and clinical trials.<\/p>\n

\u201cIf all continues to go as it has so far,\u201d Khayrallah says, \u201cwe should be in clinical trials later this year.\u201d<\/p>\n

If successful, the studies that the company plans to conduct would prepare for Phase 3 trials and eventual marketing and sales of norketotifen by another pharmaceutical company by late 2020, he says.<\/p>\n

\u201cThat\u2019s been the modus operandum for all of my companies. We do a merger or acquisition by a larger, capable partner once we have proven the concept.\u201d<\/p>\n

Khayrallah and his previous co-founders used that model for three companies they created and then exited between 2009 and 2014: Addrenex Pharmaceuticals, Neuronex and Aerial BioPharma, all of Morrisville.<\/p>\n

Addrenex, a developer of drugs to regulate the adrenergic system, was sold to Sciele Pharma, an Atlanta-based unit of Shionogi & Co. of Osaka, Japan, for $29 million in 2009.<\/p>\n

Neuronex, developer of an epilepsy drug, was sold in 2012 to New York-based Acorda for $6.8 million with additional milestone payments when the drug was submitted for approval in the U.S. (The drug did not make it to the market.)<\/p>\n

Aerial BioPharma sold the rights to its clinical-stage narcolepsy drug in 2014 to Jazz Pharmaceuticals of Dublin for $125 million in cash plus up to $272 million in potential milestone payments if the drug is approved.<\/p>\n

As with Emergo, all three companies received early stage loans from the Biotechnology Center that helped position them for follow-on investments from other sources.<\/p>\n

\u201cWhen an entrepreneur has a good idea,\u201d Khayrallah says, \u201cI\u2019ve learned that there\u2019s always potential for funding it.\u201d<\/p>","protected":false},"excerpt":{"rendered":"

DURHAM \u2013\u00a0Moise Khayrallah, Ph.D., is a serial entrepreneur with a Midas touch. Three biopharmaceutical start-ups he co-founded in recent years were quickly sold to larger companies for more than $400…<\/p>\n","protected":false},"author":1119,"featured_media":113,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"ncst_custom_author":"","ncst_show_custom_author":false,"ncst_dynamicHeaderBlockName":"ncst\/default-post-header","ncst_dynamicHeaderData":"{\"showAuthor\":true,\"showDate\":true,\"showFeaturedVideo\":false}","ncst_content_audit_freq":"","ncst_content_audit_date":"","ncst_content_audit_display":false,"ncst_backToTopFlag":"","footnotes":""},"categories":[9],"tags":[56,62,63,64,65,66,21,67,68,47],"class_list":["post-562","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-angel-investing","tag-biopharma","tag-durham","tag-emergo","tag-emergo-therapeutics","tag-flu","tag-nc-state","tag-rex","tag-rtp","tag-wolfpack-investor-network"],"displayCategory":null,"acf":[],"yoast_head":"\nWill Durham\u2019s Emergo Therapeutics be fourth big startup hit for Moise Khayrallah? - Wolfpack Investor Network<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/research.ncsu.edu\/win\/will-durhams-emergo-therapeutics-be-fourth-big-startup-hit-for-moise-khayrallah\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Will Durham\u2019s Emergo Therapeutics be fourth big startup hit for Moise Khayrallah? - Wolfpack Investor Network\" \/>\n<meta property=\"og:description\" content=\"DURHAM \u2013\u00a0Moise Khayrallah, Ph.D., is a serial entrepreneur with a Midas touch. Three biopharmaceutical start-ups he co-founded in recent years were quickly sold to larger companies for more than $400…\" \/>\n<meta property=\"og:url\" content=\"https:\/\/research.ncsu.edu\/win\/will-durhams-emergo-therapeutics-be-fourth-big-startup-hit-for-moise-khayrallah\/\" \/>\n<meta property=\"og:site_name\" content=\"Wolfpack Investor Network\" \/>\n<meta property=\"article:published_time\" content=\"2018-06-12T18:22:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-01-08T21:44:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/research.ncsu.edu\/win\/files\/2022\/12\/EmergoLogo_500x250.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1043\" \/>\n\t<meta property=\"og:image:height\" content=\"522\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Staff\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Staff\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/research.ncsu.edu\/win\/will-durhams-emergo-therapeutics-be-fourth-big-startup-hit-for-moise-khayrallah\/\",\"url\":\"https:\/\/research.ncsu.edu\/win\/will-durhams-emergo-therapeutics-be-fourth-big-startup-hit-for-moise-khayrallah\/\",\"name\":\"Will Durham\u2019s Emergo Therapeutics be fourth big startup hit for Moise Khayrallah? - Wolfpack Investor Network\",\"isPartOf\":{\"@id\":\"https:\/\/research.ncsu.edu\/win\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/research.ncsu.edu\/win\/will-durhams-emergo-therapeutics-be-fourth-big-startup-hit-for-moise-khayrallah\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/research.ncsu.edu\/win\/will-durhams-emergo-therapeutics-be-fourth-big-startup-hit-for-moise-khayrallah\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/research.ncsu.edu\/win\/files\/2022\/12\/EmergoLogo_500x250.png\",\"datePublished\":\"2018-06-12T18:22:01+00:00\",\"dateModified\":\"2024-01-08T21:44:28+00:00\",\"author\":{\"@id\":\"https:\/\/research.ncsu.edu\/win\/#\/schema\/person\/18101cc838b23e3612dd10637def18cf\"},\"breadcrumb\":{\"@id\":\"https:\/\/research.ncsu.edu\/win\/will-durhams-emergo-therapeutics-be-fourth-big-startup-hit-for-moise-khayrallah\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/research.ncsu.edu\/win\/will-durhams-emergo-therapeutics-be-fourth-big-startup-hit-for-moise-khayrallah\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/research.ncsu.edu\/win\/will-durhams-emergo-therapeutics-be-fourth-big-startup-hit-for-moise-khayrallah\/#primaryimage\",\"url\":\"https:\/\/research.ncsu.edu\/win\/files\/2022\/12\/EmergoLogo_500x250.png\",\"contentUrl\":\"https:\/\/research.ncsu.edu\/win\/files\/2022\/12\/EmergoLogo_500x250.png\",\"width\":1043,\"height\":522},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/research.ncsu.edu\/win\/will-durhams-emergo-therapeutics-be-fourth-big-startup-hit-for-moise-khayrallah\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/research.ncsu.edu\/win\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Will Durham\u2019s Emergo Therapeutics be fourth big startup hit for Moise Khayrallah?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/research.ncsu.edu\/win\/#website\",\"url\":\"https:\/\/research.ncsu.edu\/win\/\",\"name\":\"Wolfpack Investor Network\",\"description\":\"Just another Research and Innovation site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/research.ncsu.edu\/win\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/research.ncsu.edu\/win\/#\/schema\/person\/18101cc838b23e3612dd10637def18cf\",\"name\":\"Staff\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/research.ncsu.edu\/win\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/40b915144bbde2e8f65f23e26b341dde?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/40b915144bbde2e8f65f23e26b341dde?s=96&d=mm&r=g\",\"caption\":\"Staff\"},\"url\":\"https:\/\/research.ncsu.edu\/win\/author\/staff\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Will Durham\u2019s Emergo Therapeutics be fourth big startup hit for Moise Khayrallah? - Wolfpack Investor Network","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/research.ncsu.edu\/win\/will-durhams-emergo-therapeutics-be-fourth-big-startup-hit-for-moise-khayrallah\/","og_locale":"en_US","og_type":"article","og_title":"Will Durham\u2019s Emergo Therapeutics be fourth big startup hit for Moise Khayrallah? - Wolfpack Investor Network","og_description":"DURHAM \u2013\u00a0Moise Khayrallah, Ph.D., is a serial entrepreneur with a Midas touch. Three biopharmaceutical start-ups he co-founded in recent years were quickly sold to larger companies for more than $400…","og_url":"https:\/\/research.ncsu.edu\/win\/will-durhams-emergo-therapeutics-be-fourth-big-startup-hit-for-moise-khayrallah\/","og_site_name":"Wolfpack Investor Network","article_published_time":"2018-06-12T18:22:01+00:00","article_modified_time":"2024-01-08T21:44:28+00:00","og_image":[{"width":1043,"height":522,"url":"https:\/\/research.ncsu.edu\/win\/files\/2022\/12\/EmergoLogo_500x250.png","type":"image\/png"}],"author":"Staff","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Staff","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/research.ncsu.edu\/win\/will-durhams-emergo-therapeutics-be-fourth-big-startup-hit-for-moise-khayrallah\/","url":"https:\/\/research.ncsu.edu\/win\/will-durhams-emergo-therapeutics-be-fourth-big-startup-hit-for-moise-khayrallah\/","name":"Will Durham\u2019s Emergo Therapeutics be fourth big startup hit for Moise Khayrallah? - Wolfpack Investor Network","isPartOf":{"@id":"https:\/\/research.ncsu.edu\/win\/#website"},"primaryImageOfPage":{"@id":"https:\/\/research.ncsu.edu\/win\/will-durhams-emergo-therapeutics-be-fourth-big-startup-hit-for-moise-khayrallah\/#primaryimage"},"image":{"@id":"https:\/\/research.ncsu.edu\/win\/will-durhams-emergo-therapeutics-be-fourth-big-startup-hit-for-moise-khayrallah\/#primaryimage"},"thumbnailUrl":"https:\/\/research.ncsu.edu\/win\/files\/2022\/12\/EmergoLogo_500x250.png","datePublished":"2018-06-12T18:22:01+00:00","dateModified":"2024-01-08T21:44:28+00:00","author":{"@id":"https:\/\/research.ncsu.edu\/win\/#\/schema\/person\/18101cc838b23e3612dd10637def18cf"},"breadcrumb":{"@id":"https:\/\/research.ncsu.edu\/win\/will-durhams-emergo-therapeutics-be-fourth-big-startup-hit-for-moise-khayrallah\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/research.ncsu.edu\/win\/will-durhams-emergo-therapeutics-be-fourth-big-startup-hit-for-moise-khayrallah\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/research.ncsu.edu\/win\/will-durhams-emergo-therapeutics-be-fourth-big-startup-hit-for-moise-khayrallah\/#primaryimage","url":"https:\/\/research.ncsu.edu\/win\/files\/2022\/12\/EmergoLogo_500x250.png","contentUrl":"https:\/\/research.ncsu.edu\/win\/files\/2022\/12\/EmergoLogo_500x250.png","width":1043,"height":522},{"@type":"BreadcrumbList","@id":"https:\/\/research.ncsu.edu\/win\/will-durhams-emergo-therapeutics-be-fourth-big-startup-hit-for-moise-khayrallah\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/research.ncsu.edu\/win\/"},{"@type":"ListItem","position":2,"name":"Will Durham\u2019s Emergo Therapeutics be fourth big startup hit for Moise Khayrallah?"}]},{"@type":"WebSite","@id":"https:\/\/research.ncsu.edu\/win\/#website","url":"https:\/\/research.ncsu.edu\/win\/","name":"Wolfpack Investor Network","description":"Just another Research and Innovation site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/research.ncsu.edu\/win\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/research.ncsu.edu\/win\/#\/schema\/person\/18101cc838b23e3612dd10637def18cf","name":"Staff","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/research.ncsu.edu\/win\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/40b915144bbde2e8f65f23e26b341dde?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/40b915144bbde2e8f65f23e26b341dde?s=96&d=mm&r=g","caption":"Staff"},"url":"https:\/\/research.ncsu.edu\/win\/author\/staff\/"}]}},"_links":{"self":[{"href":"https:\/\/research.ncsu.edu\/win\/wp-json\/wp\/v2\/posts\/562","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/research.ncsu.edu\/win\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/research.ncsu.edu\/win\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/research.ncsu.edu\/win\/wp-json\/wp\/v2\/users\/1119"}],"replies":[{"embeddable":true,"href":"https:\/\/research.ncsu.edu\/win\/wp-json\/wp\/v2\/comments?post=562"}],"version-history":[{"count":1,"href":"https:\/\/research.ncsu.edu\/win\/wp-json\/wp\/v2\/posts\/562\/revisions"}],"predecessor-version":[{"id":1912,"href":"https:\/\/research.ncsu.edu\/win\/wp-json\/wp\/v2\/posts\/562\/revisions\/1912"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/research.ncsu.edu\/win\/wp-json\/wp\/v2\/media\/113"}],"wp:attachment":[{"href":"https:\/\/research.ncsu.edu\/win\/wp-json\/wp\/v2\/media?parent=562"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/research.ncsu.edu\/win\/wp-json\/wp\/v2\/categories?post=562"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/research.ncsu.edu\/win\/wp-json\/wp\/v2\/tags?post=562"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}